当前位置: 首页 >> 检索结果
4. Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach.
作者: Ram Prasad.;Yvonne Adu-Rutledge.;Borhane Ziani.;Jason L Floyd.;Edgar L Ready.;Sarbodeep Paul.;Fadeela Sheini.;Rati Sharma.;Robert F Rosencrans.;Sergio Li Calzi.;Micheli Severo Sielski.;Nicholas G Medawar.;Roshan Dutta.;Emory Brennis Johnson.;Xiaoping Qi.;Mohit Bansal.;Regina Lamendella.;Justin R Wright.;Suresh Kumar Verma.;Michael E Boulton.;Bruce R Stevens.;Craig W Vander Kooi.;Ramon C Sun.;Gavin Y Oudit.;Qiuhong Li.;Maria B Grant.
来源: Gut. 2025年
Both host and microbe metabolism of tryptophan (Trp) is altered in diabetes; however, the molecular mechanisms are incompletely understood.
5. Engineered virus-hunter vaccine overcomes HBV immune tolerance.
作者: Xiaoqing Chen.;Xue Liu.;Tao Xu.;Yalin Wang.;Peng Wang.;Han Liu.;Yichao Jiang.;Xiaojing Qin.;Liang Zhang.;Yueting Xiong.;Jiancheng Ding.;Yuanzhi Chen.;Fentian Chen.;Wenjing Ning.;Hongye Zeng.;Shiting Yang.;Lin Xu.;Tianying Zhang.;Quan Yuan.;Chao Liu.;Wenxin Luo.;Ningshao Xia.
来源: Gut. 2025年
Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying substantial risks of liver fibrosis, cirrhosis and hepatocellular carcinoma. Fewer than 20% of patients receiving nucleos(t)ide analogues or interferons achieve a functional cure, underscoring the urgent need for novel therapeutic strategies to improve clinical outcomes in patients with chronic HBV infection.
6. HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
作者: Edo J Dongelmans.;Lesley A Patmore.;Seng Gee Lim.;Marc Bourliere.;Shaowen Jiang.;Nathalie Ganne-Carrie.;Willem-Pieter Brouwer.;Jordan J Feld.;Yuxian Huang.;Jose A Carrion.;Teresa Broquetas.;Qiankun Hu.;Scott Fung.;Fabrice Carrat.;Fabien Zoulim.;Bettina E Hansen.;Qing Xie.;Harry L A Janssen.;Milan J Sonneveld.
来源: Gut. 2025年
Peg-interferon (peg-IFN) plays an increasingly important role in HBV cure strategies, either in combination with novel antivirals, as a lead-in or as consolidation treatment.
7. Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study.
作者: Jun Fang.;Siyi Zhong.;Tielong Wang.;Kang He.;Aibo Mu.;Meiching Ong.;Yimou Lin.;Zebin Zhu.;Ning Wang.;Jiancheng Wu.;Zhihao Wang.;Zhao Li.;Feng Gao.;Li Zhuang.;Zhiyong Guo.;Shusen Zheng.;Hao Li.;Shugeng Zhang.;Qi Ling.
来源: Gut. 2025年
Immune checkpoint inhibitors (ICIs) enable successful hepatocellular carcinoma (HCC) downstaging or bridging for liver transplantation (LT) but increase allograft rejection risk. Although immune-related adverse events (irAEs) reflect immune activation during ICI therapy, their association with post-transplant rejection remains unclear.
8. A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis.
作者: Yu Chen.;Wanneng Li.;Shuhui Wang.;Han Wang.;Jiaxin Xu.;Meiping Yu.;Lijia Wang.;Zhenghao Ye.;Xinmei Yan.;Zhuoying Lin.;Ping Han.;Fang Xiao.;Wei Yan.;Dean Tian.;Yu Lei.;Mei Liu.
来源: Gut. 2025年
Autoimmune hepatitis (AIH) is characterised by death of hepatocytes and chronic inflammation. Patients with deleterious variants in A20 are identified with AIH presentations and immune activation. However, it remains unclear how A20 dysregulation contributes to AIH pathogenesis.
9. Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.
作者: Patrick T F Kennedy.;Scott Fung.;Maria Buti.;Gurdal Yilmaz.;Wan-Long Chuang.;Tarik Asselah.;Masayuki Kurosaki.;John Jezorwski.;Vladislav Klyashtornyy.;Thierry Verbinnen.;Thomas Naoki Kakuda.;Oliver Lenz.;Carine Guinard-Azadian.;Michael Biermer.
来源: Gut. 2025年
In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, approved treatments have limited effects on hepatitis B surface antigen (HBsAg) and HBeAg.
10. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
作者: Taotao Sheng.;Raghav Sundar.;Supriya Srivastava.;Xuewen Ong.;Su Ting Tay.;Haoran Ma.;Tomoyuki Uchihara.;Benedict Shi Xiang Lian.;Takeshi Hagihara.;Mei Suen Kong.;Chang Xu.;Shamaine Wei Ting Ho.;Kie Kyon Huang.;Angie Lay Keng Tan.;Michelle Shu Wen Ng.;Jiamin Toh.;Clara Shi Ya Ng.;Vincenzo Nasca.;Chiara Carlotta Pircher.;Giovanni Randon.;Silvia Giordano.;Simona Corso.;Jeffrey Huey Yew Lum.;Joseph J Zhao.;Ming Teh.;Jimmy Bok Yan So.;Giovanna Sabella.;Shyam Prabhakar.;Jeeyun Lee.;Matthew Chau Hsien Ng.;Kohei Shitara.;Jessica Gasparello.;Matteo Fassan.;Filippo Pietrantonio.;Patrick Tan.
来源: Gut. 2025年
Human epidermal growth factor receptor 2 (HER2; ERBB2) is overexpressed or amplified in 15-20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ERBB2 expression is often variable. Although HER2 therapeutic targeting improves outcomes for HER2+ GC patients, acquired resistance is frequent.
11. Pharmacological trials of early intervention in predicted severe acute pancreatitis: implications for therapeutic window and core outcome set.
作者: Juan Lin.;Wenhao Cai.;Arjun Kattakayam.;Wenhua He.;Lu Ke.;Peter Szatmary.;Tingting Liu.;Vikesh Singh.;Rajarshi Mukherjee.;Wei Huang.;Robert Sutton.
来源: Gut. 2025年 13. Sampling the incisura angularis for the assessment of gastritis: preliminary insights from a systematic review.
作者: Luiza Fenelon.;Marcelo Cristalli Pacheco da Costa.;Matheus Vanzin Fernandes.;Diogo Bergesch Diedrich.;Murilo Cavalcante Netto do Carmo.;João Ricardo Duda.;Beanie Conceição Medeiros Nunes.;Matheus Cavalcante Franco.;Stefano Baraldo.;Robert M Genta.
来源: Gut. 2025年 14. EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
作者: Shichuan Tang.;Tingfeng Huang.;Ruijing Tang.;Kongying Lin.;Cong Luo.;Yubing Shen.;Kailing Zhang.;Yidan Tang.;Jie Kong.;Zhenwei Chen.;Jun Fu.;Qizhu Lin.;Luobin Guo.;Yeye Wu.;Yuntong Li.;Jianxi Zhang.;Zhenghong Sun.;Penghui You.;Daichang Zhang.;Yanxin Chen.;Xin Lin.;Chengqian Zhong.;Zhipeng Lin.;Hongzhi Liu.;Zuxiong Huang.;Weiping Zhou.;Peiling Dong.;Xiaolong Liu.;Hongmei Zeng.;Xiaolong Qi.;Yongyi Zeng.
来源: Gut. 2025年
The impact of nucleos(t)ide analogues (NAs) therapy on the long-term outcomes in chronic HBV infection individuals outside 2025 European Association for the Study of the Liver (EASL) strongly recommended treatment indications remains uncertain. We aimed to assess the association between NAs therapy and the risks of cirrhosis and hepatocellular carcinoma (HCC) in Chinese chronic HBV infection individuals outside these criteria.
15. Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.
作者: Shanshan Wang.;Zhengguang Guo.;Boyu Sun.;Kai Liu.;Jiashuo Chao.;Ziyu Xun.;Yunchao Wang.;Zibo Xu.;Ziyue Huang.;Hao Wang.;Yang Tan.;Nan Zhang.;Mingjian Piao.;Longhao Zhang.;Chengjie Li.;Shuofeng Li.;Jiongyuan Li.;Haidan Sun.;Feng Qi.;Aiwei Wang.;XiaoBo Yang.;Chengpei Zhu.;Hanping Wang.;Wei Sun.;Haitao Zhao.
来源: Gut. 2025年
Most patients with biliary tract cancer (BTC) do not derive durable clinical benefit (DCB) from immune checkpoint inhibitors (ICIs), underscoring the urgent need for predictive biomarkers. While urinary proteomics represents a non-invasive approach for biomarker discovery and mechanism exploration, its utility in ICI-treated patients with cancer remains unexplored.
16. Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis.
作者: Mohamed G Shiha.;Francesca Manza.;Oscar G Figueroa-Salcido.;Noé Ontiveros.;Giacomo Caio.;Claire L Jansson-Knodell.;Alberto Rubio-Tapia.;Imran Aziz.;David S Sanders.
来源: Gut. 2025年
Non-coeliac gluten/wheat sensitivity (NCGWS) is characterised by gastrointestinal and extraintestinal symptoms related to gluten or wheat ingestion in individuals without coeliac disease or wheat allergy.
17. Profiles of quantitative hepatitis B surface antigen in patients with chronic hepatitis B.
作者: Jian Wang.;Tao Fan.;Li Zhu.;Shaoqiu Zhang.;Ye Xiong.;Chao Jiang.;Juan Xia.;Renling Yao.;Xiaomin Yan.;Xingxiang Liu.;Chuanwu Zhu.;Chao Wu.;Rui Huang.
来源: Gut. 2025年 18. Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.
作者: Ana Luz Chumbe.;Suzanne M D van den Aardweg.;Anders Boyd.;Marloes Grobben.;Sylvie M Koekkoek.;Ian Zon.;Maria Prins.;Kwinten Sliepen.;Marit J van Gils.;Janke Schinkel.
来源: Gut. 2025年
Without a vaccine, HCV (re)infections continue to afflict individuals at high risk, for example, men who have sex with men (MSM).
19. First genome-wide association study reveals immune-mediated aetiopathology in idiopathic achalasia.
作者: Sandeep Grover.;Ines Gockel.;Anna Latiano.;Anna Mokrowiecka.;Pouria Dasmeh.;Mira M Wouters.;Zuzana Vackova.;Stephan L Haas.;Tania Triantafyllou.;Nicole Kreuser.;Jessica Trautmann.;Stefan Niebisch.;Timo Hess.;Rene Thieme.;Jessica Bigge.;Hubert Louis.;Eric Quertinmont.;Aline Meirhaeghe.;Manon Muntaner.;Philippe Amouyel.;Guillaume Gourcerol.;Stanislas Bruley des Varannes.;Francois Mion.;Michael Vieth.;Nikolaos Scarmeas.;Orazio Palmieri.;Francesca Tavano.;Roberto De Giorgio.;Daniela Galimberti.;Andrea Arighi.;Beatrice Arosio.;Marco Bruno.;Justyna Wasielica-Berger.;Magdalena Gawron-Kiszka.;Maria Janiak.;Magdalena Siepsiak.;Krystian Adrych.;Tomasz Marek.;Andrzej Dabrowski.;Marek Majewski.;Piotr Gietka.;Maciej Gonciarz.;Julio Pérez de la Serna.;Laisy Zacarías Martínez.;Vilmantas Giedraitis.;Lena Kilander.;Laura Fratiglioni.;Luis Miguel Real.;Julius Spicak.;Jan Tack.;Stefanie Heilmann-Heimbach.;Markus Nöthen.;Martin Ingelsson.;Caroline Graff.;Agustín Ruiz.;Jean-Charles Lambert.;Alfredo Ramirez.;Alexander J Eckardt.;Michaela Müller.;Michael Knapp.;Thaddäus T Wissinowski.;Jutta Keller.;Christiane Josephine Bruns.;Christian Gerges.;Horst Neuhaus.;Thomas Rösch.;Britta Siegmund.;Brigitte Schumacher.;Marino Venerito.;Antonio Ruiz de León.;Riccardo Rosati.;Vito Annese.;Uberto Fumagalli.;Luigi Laghi.;Elena Urcelay.;Fabienne Vavasseur.;Sabine Roman.;Pinghong Zhou.;Quanlin Li.;Zuqiang Liu.;Burkhard H A von Rahden.;Dimitris Theodorou.;Ewa Malecka-Panas.;Carlo Maj.;Ana G Vigo.;Jan Martinek.;Guy Boeckxstaens.;Johannes Schumacher.
来源: Gut. 2025年
Idiopathic achalasia (IA) is characterised by the degeneration of neurons in the myenteric plexus leading to an irreversible impaired oesophageal function. Although immune-mediated mechanisms have been proposed, the underlying aetiopathology of IA remains poorly understood.
20. SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL.
作者: Mi Zhang.;Chanyuan Chen.;Haifeng Zhang.;Tanqing Long.;Tingjie Wang.;Nanjin Ding.;Ruitao Long.;Hua Wu.;Zhilu Ma.;Zhongyu Cheng.;Junyan Tao.;Dong Kuang.;Lei Li.;Chuanrui Xu.
来源: Gut. 2025年
SIRT6 acts as a tumour suppressor in multiple cancers by regulating glucose and lipid metabolism, but its role in intrahepatic cholangiocarcinoma (ICC) remains unclear.
|